Introduction
============

In the early 1970s, a Brazilian biologist noticed that the venom of the pit viper (*Bothrops jararaca*) was able to potentiate the action of bradykinin. This discovery led to the development of teprotide. This nonapeptide is a potent angiotensin converting enzyme (ACE) inhibitor and causes hypotension in vivo. Further research expanded the knowledge of ACE inhibition and led to the introduction of captopril in 1975, the first orally active ACE inhibitor ([@b5-vhrm-4-1147]; [@b26-vhrm-4-1147]).

Trandolapril is an orally administrated ACE inhibitor that has been used for over two decades in the management of various cardiovascular disorders. This review will briefly describe the pharmacodynamic and pharmacokinetic properties of trandolapril, then discuss in more detail its use in patients with congestive heart failure (CHF) after acute myocardial infarction (AMI), in diabetic patients, in patients with arterial hypertension (HTN) and stable coronary disease, and in the prevention of proteinuria.

Pharmacodynamic and pharmacokinetic properties
==============================================

Trandolapril is a non-sulfhydryl prodrug that is rapidly hydrolyzed in the liver to the active diacid compound, trandolaprilat. Trandolaprilat has a high binding affinity for ACE and the drug concentration required to inhibit ACE activity by 50% (IC~50~) is less than that of enalaprilat, captopril and quinaprilat, and similar to that of ramiprilat ([@b62-vhrm-4-1147]). Maximal ACE inhibition after repeated doses occurs at 3 hours in younger patients and at 1.5 hours in older patients ([@b4-vhrm-4-1147]). Trandolapril is a highly lipophilic drug, which may facilitate tissue ACE inhibition with potential effects in cardiovascular remodeling ([@b62-vhrm-4-1147]). The main pharmacodynamic effects of trandolapril are achieved by a reduction in plasma angiotensin-II levels. This leads to a reduction in peripheral vasoconstriction, blood pressure, total peripheral resistance, and decreased sodium and water retention by the kidney. ACE inhibitors increase bradykinins production, which explains their main side effect of dry cough ([Figure 1](#f1-vhrm-4-1147){ref-type="fig"}).

Several small size non-blinded pharmacodynamic studies were done to assess cardiovascular effects of trandolapril. In one study of 27 hypertensive patients aged 18--75, plasma norepinephrine levels were either statistically unchanged or decreased (17%--32%). In this trial, a single-blind, 2-week placebo run-in period was followed by 2 double-blind crossover periods, each of 4 weeks, when patients were randomized to receive either 2 mg trandolapril once daily or matching placebo ([@b48-vhrm-4-1147]). In another trial of heart failure patients with NYHA class III or early class IV symptoms, neurohumoral activation was attenuated and plasma epinephrine decreased (32%) ([@b61-vhrm-4-1147]). All patients had heart failure symptoms combined with a cardiothoracic ratio \> 0.50 on chest x-ray and/or left ventricular (LV) ejection fraction ≤ 0.35 and/or capillary wedge pressure \>15 mmHg, and previous treatment with ACE inhibitors was stopped for at least 1 week before ([@b61-vhrm-4-1147]). Cardiac performance indices (LV stroke work and volume) were also significantly increased ([@b61-vhrm-4-1147]). In other small studies, significant reductions were observed in total peripheral resistance (13%--23%), LV hypertrophy and remodeling (LV mass index 24%), end-systolic stress (8%--12%), pulmonary capillary wedge pressure (43%--45%), and pulmonary artery pressure (29%) ([@b13-vhrm-4-1147]; [@b22-vhrm-4-1147]; [@b61-vhrm-4-1147]).

The bioavailability of trandolapril is not affected by concomitant food intake. One third of the drug is excreted in the urine and the remaining two thirds in feces ([@b62-vhrm-4-1147]). Dosage reduction is recommended in patients with severe renal failure, since renal clearance of trandolapril is directly proportional to creatinine clearance ([@b11-vhrm-4-1147]). In healthy volunteers, no significant interactions were observed when trandolapril was co-administered with most frequently used cardiovascular (CV) drugs including warfarin ([@b62-vhrm-4-1147]; [@b40-vhrm-4-1147]).

Therapeutic use
===============

Patients with LV dysfunction after myocardial infarction (MI)
-------------------------------------------------------------

The TRAndolapril Cardiac Evaluation (TRACE) study assessed the effect of ACE inhibition with trandolapril on mortality (overall and cardiovascular) and cardiovascular morbidity in patients surviving an AMI with reduced LV function ([@b59-vhrm-4-1147]). TRACE was a randomized, double-blind, placebo-controlled study conducted in 27 centers in Denmark. Eligible patients had an AMI confirmed by elevated cardiac enzymes, electrocardiographic changes, and/or chest pain and reduced LV function confirmed by an echocardiography-derived wall motion score index (WMSI) ≤1.2. A WMSI ≤1.2 approximates a left ventricular ejection fraction ≤35% in the nine-segment model originally described by [@b27-vhrm-4-1147]. Patients with residual ischemia and/or clinical heart failure were not excluded. Only the following exclusion criteria were used: an absolute or relative contraindication or a definite need for ACE inhibition; severe, uncontrolled diabetes mellitus; hyponatremia (\<125 mmol/L sodium); an elevated serum creatinine level (2.3 mg/dL \[200 mmol/L\]); pregnancy or lactation; acute pulmonary embolism; vascular collagen disease; non-ischemic obstructive heart disease; unstable angina requiring immediate invasive therapy; severe liver disease; neutropenia or concurrent immunosuppressive or antineoplastic therapy; drug or alcohol abuse; or treatment with another investigational drug. Trandolapril or placebo was added to conventional therapy 3 to 7 days after AMI (mean 4.5 days). Between May 1990 and June 1992, 6674 patients (7010 infarctions) were screened. A total of 2614 patients had a wall motion index ≤1.2; of these, 1749 were included, with a follow-up of 24 to 50 months. Overall 1-year mortality in the study was 24% ([@b59-vhrm-4-1147]).

Baseline characteristics showed no significant differences except the use of nitrates, which was higher in the active drug group (p \< 0.005) ([@b33-vhrm-4-1147]). Mean age was 67 years and 70% of the population were males. 47% had had an anterior Q wave MI and 21% of patients had a Killip class ≥2 at randomization. The study was done in the early 1990s with 90% receiving aspirin, 16% β-blockers, 28% calcium channel antagonists and around 30% digoxin or digitalis ([@b33-vhrm-4-1147]).

During the study period, 304 patients (34.7%) in the trandolapril group died, compared with 369 (42.3%) in the placebo group (p = 0.001) ([@b33-vhrm-4-1147]) ([Figure 2](#f2-vhrm-4-1147){ref-type="fig"}). The relative risk (RR) of death from any cause in the trandolapril group, compared with the placebo group, was 0.78 (95% confidence interval \[CI\] 0.67--0.91; p = 0.001), mostly from cardiovascular causes (226 vs 288 in the trandolapril and placebo groups respectively, RR 0.75, 95% CI 0.63--0.89, p = 0.001). Fewer patients died suddenly in the trandolapril vs the placebo group (105 vs 133, RR 0.76, 95% CI 0.59--0.98, p = 0.03). Time to other endpoints such as reinfarction and severe heart failure are shown in [Figure 3](#f3-vhrm-4-1147){ref-type="fig"}.

Several long term follow-up and secondary analyses of the TRACE study have addressed additional aspects of trandolapril use after AMI. First, the prognostic importance of atrial fibrillation (AF) development and the impact of trandolapril have been studied. Of all patients enrolled (trial or registry), sustained or paroxysmal AF or atrial flutter (AFL) was observed in 1149 patients (19%) during hospitalization ([@b45-vhrm-4-1147]). During follow-up, 1659 patients (34%) in the registry died: 482 (50%) patients with AF/AFL and 1177 (30%) patients without AF/AFL, p \< 0.001. Sudden cardiac death (SCD) occurred in 536, non-SCD occurred in 725, and 398 died of non-cardiovascular causes (including 142 unclassifiable cases). The adjusted risk ratio of AF/AFL for total mortality was 1.33 (95% CI 1.19--1.49; p \< 0.0001), 1.31 for SCD (95% CI 1.07--1.60, p \< 0.009) and 1.43 for non-SCD (95% CI 1.21--1.70, p \< 0.0001). Therefore, after an AMI, AF/AFL are associated with increased mortality, both from SCD and non-SCD ([@b45-vhrm-4-1147]). In the TRACE study, AF developed in only 2.8% of patients receiving trandolapril compared with 5.3% in the placebo group (p \< 0.05), even after multivariate analyses ([@b46-vhrm-4-1147]). More recently, ACE inhibition has been shown to prevent new-onset AF, facilitate direct current cardioversion and maintain sinus rhythm ([@b30-vhrm-4-1147]). A complete discussion on this topic is beyond the scope of this article and may be found elsewhere ([@b44-vhrm-4-1147]).

Most of the data on ACE inhibition and heart failure after AMI have limited follow-up duration, owing to the nature of randomized trials. An extended follow-up from TRACE ([@b7-vhrm-4-1147]) has been published, focusing on long term survival (more than 10 years) and hospital admission occurring during and beyond the randomized phase of the study. The mortality curves between patients initially allocated to trandolapril or placebo started to diverge during the first year, favoring trandolapril, and remained thereafter. The Kaplan--Meier estimate of mortality at 10 years was 71.5% in the placebo group and 69.5% in the trandolapril group. For the entire follow-up, trandolapril significantly reduced the risk of death from any cause compared with placebo (RR 0.89, 95% CI 0.80--0.99, p = 0.031) ([Figure 4](#f4-vhrm-4-1147){ref-type="fig"}), all causes hospital admissions (RR 0.92, 95% CI 0.88--0.96, p \< 0.001) and cardiac hospitalizations (RR 0.95, 95% CI 0.91--1.00, p = 0.047), the majority being for heart failure ([@b7-vhrm-4-1147]). These data suggest an early benefit of ACE inhibition after AMI and persistent effects over time, beyond the randomized trial duration, a period after which most patients initially allocated to placebo will have been switched to an ACE inhibitor.

Diabetic patients with left-ventricular dysfunction after MI
============================================================

A growing body of evidence indicates that regulation of the rennin--angiotensin system is important for the prevention of cardiovascular events, not only in hypertensive patients, but also in diabetics; they are considered high risk with markedly increased mortality after AMI, almost double that of patients without diabetes. This excess mortality seems to be related to congestive heart failure and reinfarction episodes ([@b64-vhrm-4-1147]; [@b19-vhrm-4-1147]; [@b38-vhrm-4-1147]; [@b35-vhrm-4-1147]). ACE inhibition is beneficial in these patients, mainly through prevention of LV remodeling ([@b10-vhrm-4-1147]). Other mechanisms have also been suggested such as improvement in: fibrinolytic balance, endothelial function, sympathovagal balance and glycemic control, in addition to preservation of renal function ([@b24-vhrm-4-1147]).

A subgroup analysis of diabetics patients enrolled in TRACE showed that ACE inhibition with trandolapril is beneficial in this population. As previously mentioned, diabetic patients had a worse prognosis than non-diabetic patients, but prognosis was improved with ACE inhibitor treatment, with a RR for total mortality of 0.64 (95% CI: 0.45--0.91) compared with placebo, after multivariate analysis including age, gender, body mass index, smoking, previous MI, hypertension, AF, CHF, residual angina and WMSI ([@b24-vhrm-4-1147]) ([Figure 5](#f5-vhrm-4-1147){ref-type="fig"}). Interestingly, in diabetics treatment with trandolapril compared to placebo reduced all secondary endpoints by approximately 50%. Of particular interest was the marked reduction in the progression toward severe heart failure with trandolapril (RR = 0.38, 95% CI: 0.21--0.67). For the non-diabetic patients, only cardiovascular death was reduced significantly with ACE inhibitor treatment (RR 0.79, 95% CI 0.66--0.96).

In a small randomized trial of type 2 diabetes patients, coronary flow velocity reserve improved after treatment with an ACE inhibitor but not with an angiotensin-II receptor antagonist, suggesting that ACE inhibition might have beneficial effects on coronary microangiopathy associated with type 2 diabetes ([@b31-vhrm-4-1147]). In an experimental model of diabetes, this condition was associated with decreased myocardial capillary supply, which was reversed by ACE inhibition, but not by endothelin-1 receptor blockade. Attenuation of cardiac fibrosis deposition with ACE inhibitor was also seen ([@b20-vhrm-4-1147]).

The prognostic importance of optimal glycaemia control has been recently recognized. Hence the effects on glucose metabolism of the beta-blocker atenolol and the ACE inhibitor trandolapril were investigated in patients with primary hypertension, using a small, randomized, double-blind, parallel-group design. After 48 weeks of treatment, insulin sensitivity was reduced by 23% using atenolol, while it remained unchanged with trandolapril (+0.5%, p = 0.0010) ([@b53-vhrm-4-1147]). Although interesting, the subject remains highly controversial ([@b48-vhrm-4-1147]; [@b42-vhrm-4-1147]). Nevertheless, there is additional evidence that ACE inhibitor with trandolapril improves the progression of diabetic peripheral neuropathy ([@b37-vhrm-4-1147]; [@b57-vhrm-4-1147]; [@b36-vhrm-4-1147]).

ACE inhibition in stable coronary artery disease
================================================

The concept of vascular protection has been proposed after retrospective analysis from both SOLVD and SAVE has suggested reduced recurrent MI in HF patients allocated to ACE inhibitor compared with placebo. Hence large scale trials have been designed to test this hypothesis. The first two trials with ACE inhibitors have been undertaken in high-risk patients with either coronary artery disease (CAD) without symptomatic heart failure, pre-existing vascular disease, or diabetes combined with an additional cardiovascular risk factor. In these situations, ACE inhibition with ramipril or perindopril leads to reduced rates of the combined endpoint of death from cardiovascular causes, acute MI or stroke in the Heart Outcomes Prevention Evaluation (HOPE) trial ([@b63-vhrm-4-1147]) or the combined endpoint of cardiovascular death, MI, or cardiac arrest in the European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) trial ([@b15-vhrm-4-1147]). These two trials are similar and enrolled patients at increased risk of adverse cardiovascular events. Although patients with symptomatic heart failure were excluded from these trials, there was no requirement for LV ejection fraction measurement and the brain natriuretic peptide biomarker was not available at that time. Nevertheless, the concept of vascular protection with ACE inhibitor was supported by these studies.

The goal of the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) trial was to test whether ACE inhibitor therapy, when added to modern conventional therapy, would reduce the rate of non-fatal MI, death from cardiovascular causes, or revascularization in patients with stable coronary artery disease and normal or slightly reduced LV function ([@b6-vhrm-4-1147]). PEACE enrolled patients aged 50 years or older with coronary artery disease documented by at least one of the following: MI at least 3 months before enrolment; coronary-artery bypass grafting or percutaneous transluminal coronary angioplasty at least 3 months before enrolment; obstruction of ≥50% of the luminal diameter of at least one native vessel on coronary angiography and left ventricular ejection fraction \>40% on contrast or radionuclide ventriculography or echocardiography; a qualitatively normal left ventriculogram; or the absence of LV wall-motion abnormalities on echocardiography. Patients hospitalized for angina within the preceding 2 months were excluded as well as any other unstable cardiac or non-cardiac condition. The original endpoint was reduction in cardiovascular death or non-fatal MI, and required a sample size of 14,100 patients. Due to recruiting difficulties, this primary endpoint was changed by the steering committee, to include coronary revascularization, which reduced the sample size to 8100. The original primary endpoint became a secondary endpoint. Of the 8290 patients who underwent randomization, 4158 were assigned to receive trandolapril and 4132 matching placebo. Compliance with the target trandolapril dose (4 mg) was 68.4% in the treatment group and 77.7% in the placebo group. The median follow-up was 4.8 years. Baseline characteristics include patients' mean (± SD) age of 64 ± 8 years and 18% of patients enrolled were women. 55% had a previous MI, 72% had undergone at least one coronary-revascularization procedure, and 17% were known to have diabetes. A quantitative ejection fraction was available for 95% of the cohort, with a mean value of 58 ± 9%; for the remaining 5%, a two-dimensional echocardiogram reported normal LV function by qualitative assessment. 70% of patients were using lipid-lowering drugs. The average serum cholesterol concentration was 192 mg/dL (5 mmol/L) ([@b6-vhrm-4-1147]). The incidence of the new primary endpoint was 22.5% in the placebo group and 21.9% in the trandolapril group (HR 0.96, 95% CI 0.88--1.06, p = 0.43) ([@b6-vhrm-4-1147]) ([Figure 6](#f6-vhrm-4-1147){ref-type="fig"}). Side effects leading to discontinuation of the study medication occurred in 6.5% of the patients in the placebo group and 14.4% of those in the trandolapril group (p \< 0.001), mainly due to cough (39.1% vs 27.5%, p \< 0.01) and syncope (4.8% vs 3.9%, p = 0.04), which were higher in the trandolapril group ([@b6-vhrm-4-1147]). Angioedema was reported in 5 patients in the placebo group (2 were openly taken ACE inhibitors) and in 8 patients in the trandolapril group.

Compared with previous studies, patients in the PEACE trial were at lower risk of death from cardiovascular causes, non-fatal MI or stroke than patients enrolled in the HOPE or EUROPA trials, as can be appreciated in [Figure 7](#f7-vhrm-4-1147){ref-type="fig"}. This might, in part, explain the neutral results of this large trial. Moreover, patients in the PEACE trial were more aggressively treated (more previous revascularization and more intensive management of risk factors) than patients in the previous trials. In particular, the level of LDL cholesterol and lipid lowering treatment used (statins) are important. ACE inhibitors and statins have a common mechanism of action: they both reduce activation of the lectin-like oxidized LDL receptor and thus reduce oxidation of LDL cholesterol. If the concentration of LDL cholesterol is sufficiently low, ACE inhibitors may no longer be effective in reducing the rate of cardiovascular events ([@b49-vhrm-4-1147]).

In spite of these neutral results, current guidelines recommend ACE inhibition in CAD patients with other indications for these agents, such as hypertension, LV systolic dysfunction with/without prior MI, symptomatic heart failure or diabetes ([@b3-vhrm-4-1147]). In revascularized CAD patients treated with aspirin and statins, and no formal indication for ACE inhibitor treatment, the benefit should perhaps be weighed against the cost, risk and side effects.

Patients with hypertension
==========================

ACE inhibitors have been used since the 1970s for the treatment of hypertension (HTN). Their advantage in this population not only lies in secondary beneficial effects of reduction in levels of angiotensin-II, but also in decreased catecholamine levels and vascular remodelling, among others. Trandolapril has been approved by the US Food and Drug Administration in the US in 1996 and in Canada in 1997 for the treatment of patients with mild to moderate hypertension. Many controlled clinical trials have found that trandolapril, alone or in combination with other antihypertensive agents, produces clinically significant blood pressure (BP) reductions and achieves target BP levels in patients with primary HTN ([@b39-vhrm-4-1147]; [@b22-vhrm-4-1147]; [@b8-vhrm-4-1147]; [@b43-vhrm-4-1147]; [@b21-vhrm-4-1147]; [@b47-vhrm-4-1147]; [@b60-vhrm-4-1147])

TRAIL (The Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients) was a 26-week, prospective, open-label, multicenter study in Canadian primary care centers ([@b60-vhrm-4-1147]). Subjects with HTN stages I and II according to the 7-JNC ([@b9-vhrm-4-1147]) who were treatment naive or whose disease was uncontrolled on current first-line antihypertensive monotherapy, were treated with trandolapril alone or in addition to their current regimen. Trandolapril was started at 1 mg and was titrated to 2 or 4 mg. The purpose of the study was to evaluate the effectiveness of escalating-dose regimen of trandolapril in HTN management. In the total cohort, 71% of patients reached adequate BP control according current guidelines (\<140/90 mmHg in subjects with no other risk factors and \<130/80 mmHg in patients with kidney disease or diabetes) after 2 weeks of treatment and 73.4% after 26 weeks. Optimal BP control was equally achieved in naive patients as well as in patients already treated but with sub-optimal BP control.

INVEST (The INternational VErapamil-Trandolapril Study) was a randomized, open label study of 22,576 hypertensive CAD patients aged 50 years or older, conducted from September 1997 to February 2003 at 862 sites in 14 countries ([@b47-vhrm-4-1147]). The combined primary endpoint was death (all cause), or first occurrence of non-fatal MI or non-fatal stroke. Other endpoints included cardiovascular death, angina, adverse reactions, hospitalizations, and blood pressure control at 24 months. Patients were randomly assigned to verapamil sustained release or atenolol. Subsequently, trandolapril (for the calcium channel blocker \[CCB\] group) and hydrochlorothiazide (for the beta blocker \[BB\] group) were added if needed to achieve BP target levels according to the 6-JNC guidelines. Trandolapril was also recommended when there was a clear clinical indication such as for patients with heart failure, diabetes or renal impairment. The mean follow-up was 2.7 years. A primary outcome event occurred in 9.93% of the patients in the CCB group vs 10.17% in the BB group, with a RR of 0.98 (95% CI 0.90--1.06). Two-year BP control was similar in the two groups, demonstrating that the verapamil--trandolapril strategy was as effective as the atenolol--hydrochlorothiazide strategy. The INVEST trial was designed to have a short follow-up which may explain the lack of statistical power to demonstrate a reduction in hard endpoints.

A retrospective analysis from TRACE on the subgroup of patients with hypertension confirmed the worse prognosis of HTN after AMI compared with patients without HTN ([@b23-vhrm-4-1147]). 173 patients (43%) with a medical history of hypertension at randomization (the hypertensive group) died during follow-up, versus 500 (37%) without HTN history. Of note, treatment with trandolapril resulted in a profound beneficial effect in this population, with a RR of death from any cause for the hypertensive group of 0.59 (95% CI 0.44--0.80) in the trandolapril group compared with placebo, versus 0.85 (95% CI 0.72--1.02) for normotensive patients allocated to the ACE inhibitor ([@b23-vhrm-4-1147]). The interaction between the diagnosis of HTN and the benefit of trandolapril treatment was highly significant (p \< 0.001) ([@b23-vhrm-4-1147]).

Prevention of proteinuria
=========================

Many trials have shown that not only inadequate diabetes control (reflected by elevated glycosylated hemoglobin), but also hypertension, dyslipidemia, cigarette smoking, old age, insulin resistance, male sex, and afro-Caribbean, Asian or native American origin are strong risk factors for the development of diabetic nephropathy ([@b17-vhrm-4-1147]; [@b32-vhrm-4-1147]; [@b51-vhrm-4-1147]). In normal subjects, an elevated preglomerular vascular resistance protects the glomerular microcirculation from systemic BP variations. In patients with diabetic nephropathy, this protective mechanism is blunted and vasodilatation of the afferent (preglomerular) vessels occurs, permitting the systemic BP variation to be transmitted to the glomerular bed. Hence, strict BP control is mandatory in these patients in order to avoid further glomerular damage. In diabetic nephropathy, typical histological progressive changes in the glomerular structure can be found, which leads at first to microalbuminuria, followed by selective albuminuria and later on to non-selective protein excretion with a progressive decline in renal function and end-stage renal failure.

Microalbuminuria has been extensively studied as a risk factor for cardiovascular outcomes, mostly in patients with diabetes mellitus ([@b55-vhrm-4-1147]). This association has been also observed in patients with vascular diseases ([@b18-vhrm-4-1147]), electrocardiographic ST-T segment changes ([@b14-vhrm-4-1147]) and those with hypertension ([@b34-vhrm-4-1147]; [@b1-vhrm-4-1147]; [@b12-vhrm-4-1147]). At first, it was thought that proteinuria reduction and renal protection induced by ACE inhibitors were primarily due to vasodilatation of the efferent arteriole with subsequent decrease in glomerular capillary pressure ([@b41-vhrm-4-1147]). However, ACE inhibitors play an additional role in glomerular function by modifying glomerular size and permeability and increasing negative electric charge in the glomerular membrane ([@b2-vhrm-4-1147], [@b52-vhrm-4-1147]).

The MIcroalbuminuria, Cardiovascular, and Renal Outcomes in HOPE (MICRO-HOPE) substudy showed that ramipril treatment was associated with a decreased risk of development of overt nephropathy in patients enrolled in HOPE and evidence of microalbuminuria at baseline ([@b28-vhrm-4-1147]). Likewise, the BENEDICT (BErgamo NEphrologic DIabetes Complications Tial) evaluated whether a combination therapy of ACE inhibitor and CCB was better than either class alone or placebo in decreasing the progression toward microalbuminuria in normoalbuminuric patients with type 2 diabetes and hypertension ([@b54-vhrm-4-1147]). In BENEDICT, 1204 patients were randomized to either a combination of trandolapril and verapamil, trandolapril alone, verapamil alone or placebo. Median follow-up was 3.6 years. A total of 601 subjects received an ACE inhibitor (alone or with verapamil) and 603 subjects did not. Persistent microalbuminuria, the primary endpoint, was reached in 35 (5.8%) subjects who received an ACE inhibitor-based therapy and in 66 (10.9%) in subjects who did not. This difference was statistically significant (p \< 0.001) even after adjustment for site, age, sex, smoking status, diastolic BP and log-transformed urinary albumin excretion at baseline ([Figure 8](#f8-vhrm-4-1147){ref-type="fig"}). At the end of the study, patients in the trandolapril group (alone or in combination with verapamil) had a lower BP than patients in the verapamil group alone.

The PROCOPA study was designed to compare whether the magnitude of proteinuria reduction with different classes of anti-hypertensive agents differs, while similar BP reduction is achieved ([@b50-vhrm-4-1147]). It was a prospective, randomized, double-blind, controlled trial. Inclusion criteria included: BP \> 130/85 mmHg, primary renal disease, proteinuria \>1 g/day and creatinine clearance ≥50 mL/min. After a run-in period, patients were randomized to atenolol, trandolapril, verapamil or a combination of verapamil and trandolapril for 6 months. There was no statistically significant difference in BP control between groups. However, a significant fall in protein urinary excretion was obtained in the ACE inhibitor-based strategy (both trandolapril/verapamil combination and trandolapril-alone groups), suggesting that in spite of adequate and similar BP control provided by the four classes of agents, only ACE inhibition reduces proteinuria in primary renal disease. No angiotensin-II receptor blockers were included in this trial.

Advantages of trandolapril over other ACE inhibitors
====================================================

Appropriate, recommended and optimal dosage with ACE inhibitors is becoming more prominent in cardiovascular literature ([@b16-vhrm-4-1147]; [@b25-vhrm-4-1147]). There is solid evidence from pharmacokinetic and hard endpoint clinical trials for the optimal trandolapril dosage to use. Despite the fact that most ACE inhibitors are recommended for once-daily administration, only fosinopril, ramipril and trandolapril have trough-to-peak effect ratios in excess of 50% ([@b56-vhrm-4-1147]). Other ACE inhibitors, such as perindopril, have obtained indication for heart failure with a dosage of 4 mg daily, but should it be 8 mg or even 16 mg per day? Current US guidelines for the management of chronic heart failure acknowledge this problem and they do not establish a precise recommended dosage for enalapril, lisinopril or perindopril ([@b29-vhrm-4-1147]). The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology also leave the clinician with this dilemma. Therefore in Europe, only enalapril (10 mg twice a day) and trandolapril (4 mg daily) have precise recommended evidence-based dosage ([@b58-vhrm-4-1147]).

Conclusion
==========

Trandolapril is a well studied, safe and effective ACE inhibitor with clinically convenient pharmacological properties. It is widely used in the management of cardiovascular disorders in different populations, such as patients with hypertension and diabetic patients with coronary artery disease, and especially in the prevention and management of proteinuria. Particularly, there is a sound evidence-based support for trandolapril 4 mg once a day in post-MI patients with LV dysfunction regardless of heart failure symptoms.
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